Fifth Third Bancorp Has $1.91 Million Holdings in Enovis Corporation $ENOV

Fifth Third Bancorp grew its holdings in Enovis Corporation (NYSE:ENOV) by 50,442.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,901 shares of the company’s stock after acquiring an additional 83,735 shares during the quarter. Fifth Third Bancorp’s holdings in Enovis were worth $1,909,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC increased its position in Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,072 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after purchasing an additional 73,116 shares during the period. Empowered Funds LLC grew its position in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Finally, Amundi increased its holdings in shares of Enovis by 24,405.0% during the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after purchasing an additional 9,762 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

Shares of Enovis stock opened at $26.57 on Thursday. The firm has a market cap of $1.53 billion, a P/E ratio of -1.34 and a beta of 1.39. The firm’s 50-day simple moving average is $23.60 and its 200-day simple moving average is $23.76. Enovis Corporation has a twelve month low of $19.14 and a twelve month high of $34.28. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The firm had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts expect that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Insider Activity

In related news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders purchased 4,200 shares of company stock valued at $92,084. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the subject of a number of research analyst reports. BMO Capital Markets started coverage on shares of Enovis in a research report on Wednesday, July 8th. They set an “outperform” rating and a $29.00 price objective for the company. Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 30th. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price target on shares of Enovis in a report on Friday, May 22nd. Wells Fargo & Company reduced their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Evercore set a $32.00 price objective on Enovis in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and an average price target of $41.71.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.